- Home
- NMAI vs CATX Comparison
NMAI vs CATX Comparison
Compare NMAI & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | CATX |
|---|---|---|
| Founded | 2021 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.9M | 497.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NMAI | CATX |
|---|---|---|
| Price | $13.99 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 101.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.99 | $1.96 |
| 52 Week High | $14.38 | $6.16 |
Technical Indicators
Market Signals| Indicator | NMAI | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 56.57 | 49.91 |
| Support Level | $12.64 | $3.93 |
| Resistance Level | $14.38 | $4.20 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 42.65 | 66.91 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.